New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
10:37 EDTCYTK, CLDX, INCY, TWTR, DISHOptions with increasing implied volatility: CYTK CLDX INCY TWTR DISH
News For CYTK;CLDX;INCY;TWTR;DISH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 21, 2014
16:00 EDTTWTROptions Update; October 21, 2014
Subscribe for More Information
10:00 EDTTWTROn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:55 EDTDISHBlackout not 'game changer' for Time Warner, DISH, says Wells Fargo
Wells Fargo believes the removal of several of Time Warner's (TWX) Turner channels from DISH's (DISH) line-up will not be a "game changer" for either company. Wells notes the majority of Time Warner's affiliate growth comes from TNT and TBS networks, and it does not expect the channel loss to impact DISH's subscriber trends. The firm expects the networks to come back to DISH "eventually."
09:37 EDTTWTRActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR AMZN C TWTR CVX VZ MCD GILD TXN
07:54 EDTINCYLeerink a buyer of Alkermes, ImmunoGen, Incyte
Subscribe for More Information
07:49 EDTTWTRTwitter October weekly volatility flat into developerís conference
Twitter October weekly call option implied volatility is at 51, November is at 67, December is at 58, January at 53; compared to its 26-week average of 54 according to Track Data, suggesting non-directional near term price movement into its developerís conference on October 22.
06:26 EDTTWTRTwitter expected to announce tools for app makers, WSJ reports
Twitter is expected to announce on Wednesday a suite of tools through an app-development platform called "Fabric" that will make it easier for programmers to build apps, sources tell the Wall Street Journal. The services are expected to address issues that affect mobile developers, like tracking analytics. Reference Link
06:09 EDTTWTRTwitter initiated with a Neutral at Citigroup
Subscribe for More Information
05:05 EDTDISHDISH reports Turner removes channels after contract deadline
Subscribe for More Information
October 20, 2014
13:40 EDTDISHOptions with increasing implied volatility
Subscribe for More Information
11:37 EDTTWTRStocks with call strike movement; X TWTR
Subscribe for More Information
09:36 EDTCLDXActive equity options trading on open
Subscribe for More Information
07:37 EDTCYTKCytokinetics completes review results from BENEFIT-ALS regarding tirasemtiv
Cytokinetics provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. The company announced that it has completed its review of results from BENEFIT-ALS and has concluded that effects observed on Slow Vital Capacity in patients treated with tirasemtiv are robust and potentially clinically meaningful. In addition, following consultation with clinical and statistical experts, the company believes that data from BENEFIT-ALS support progression of tirasemtiv to a potential Phase III clinical trial in patients with amyotrophic lateral sclerosis (ALS). The company also announced that it has begun regulatory interactions with the U.S. Food and Drug Administration regarding results from BENEFIT-ALS and has received initial feedback from the FDA. The company believes that effects on SVC could be a Phase III clinical trial endpoint and could support registration of tirasemtiv as a potential treatment for patients with ALS. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015. Cytokinetics has received feedback from the FDA following initial communications regarding tirasemtiv and BENEFIT-ALS. The company believes that the FDA may be willing to consider a potential registration path for tirasemtiv relating to effects on SVC. The company expects to have additional interactions with the FDA and other regulatory authorities. In addition, the company has commenced Phase III readiness activities including designing a potential Phase III clinical trial in order to inform plans, timelines and costs associated with the further development of tirasemtiv.
05:59 EDTDISHStocks with implied volatility above IV index mean; DISH AMZN
Subscribe for More Information
October 19, 2014
17:39 EDTDISHDish's AutoHop wins wins tentative ruling over Fox, Bloomberg says
Subscribe for More Information
October 17, 2014
16:01 EDTTWTROptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
12:17 EDTTWTRMark Cuban says buying Netflix shares, sees company as M&A target
Subscribe for More Information
10:51 EDTDISHOptions with increasing implied volatility
Options with increasing implied volatility: COV DISH HLT QEP GREK BKW BYI LLY DTV TIBX
09:38 EDTTWTRActive equity options trading on
Subscribe for More Information
08:01 EDTINCYIncyte names Gryska CFO to succeed Hastings
Incyte announced the appointment of David Gryska as Executive Vice President and CFO, effective October 31. Gryska will succeed David Hastings, who has served as Incyteís Executive Vice President and CFO since October 2003. Hastings, who is leaving the company to pursue other opportunities, will remain with Incyte through the end of November and will work closely with Gryska to ensure a seamless transition.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use